Navigation Links
ViaCyte, Inc., Receives Three Additional U.S. Patents, Supporting its Development of a Stem Cell Derived Treatment for Diabetes
Date:5/5/2010

SAN DIEGO, May 5 /PRNewswire/ -- ViaCyte, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today that it has received three additional U.S. Patents:

On April 13, the Company was granted U.S. Patent 7,695,963, entitled "Methods for Increasing Definitive Endoderm Production".  Methods described in this patent can improve the yield in manufacturing of definitive endoderm and also cells derived from it.

On April 13, the Company was also granted U.S. Patent 7,695,965, entitled "Methods of Producing Pancreatic Hormones".  This patent describes treatment of diabetes with pancreatic progenitor cells derived from human pluripotent stem cells, which develop and mature in vivo to secrete insulin in response to blood glucose levels.  The '965 patent builds on the Company's earlier U.S. Patent 7,534,608, which issued in May 2009.

On April 27, the Company was granted U.S. Patent 7,704,738, entitled "Definitive Endoderm".  The patent has claims covering a method of producing definitive endoderm.  This method has been widely adopted in the field.  It builds on the Company's landmark U.S. Patent 7,510,876, which issued in March 2009.

These new patents add substantially to the Company's U.S. patent estate.  The Company also has a growing number of patents granted outside the United States.  These patents further underscore ViaCyte's leadership position in developing stem cell based therapies for diabetes.  The Company has focused on this development for almost ten years and is increasingly recognized for its science and IP as a result of this focus.

About ViaCyte, Inc.

ViaCyte (formerly Novocell, Inc.) is a preclinical therapeutic company focused on diabetes.  Our therapy is based on pancreatic beta cell progenitors (Pro-Islet™) derived from human pluripotent stem cells.  These cells are implanted using a durable and retrievable encapsulation device.  Once implanted and matured, these cells secrete insulin in response to blood glucose levels. The Company's goal is long term insulin independence without immune suppression, and without hypoglycemia and other diabetes-related complications.

ViaCyte is a private company headquartered in San Diego, California, with additional operations in Athens, Georgia.  The Company is funded in part through the support of the California Institute for Regenerative Medicine.

This news release may contain forward-looking statements made pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE ViaCyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Patient Safety Technologies, Inc., Contracts to Implement the Safety-Sponge(TM) System at The Mount Sinai Hospital in New York
2. OMNIlife science, Inc., Announces U.S. Distribution Agreement with SERF-Dedienne Sante of France for its ION free Large Diameter Head Dual Mobility Acetabular Cup System
3. NeoMatrix, Inc., Awarded New Technology Agreement by Novation for HALO(R) Breast Pap Test
4. Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive
5. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
6. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
7. Nyer Medical Group, Inc., Announces Agreements to Sell Certain Eaton Apothecary Assets to Walgreens and Sell Operating Subsidiarys Stock to Investors
8. BioStorage Technologies, Inc., Accelerates European Expansion with Opening of New German Facility
9. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
10. CardioVascularCS.Org, a division of EndoVascular Forum, Inc., Partners with Complex Interventional Cardiovascular Therapy (CICT) to Extend Electronic Medical Care Advancement
11. CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American ... function testing company, is now able to perform sophisticated lung assessments ... ndd Medical Technologies , Inc. Patients are no ...  Thanks to ndd,s EasyOne PRO ® , ARL patients like Jeanne ... needed testing done in the comfort of her own home. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
Breaking Medicine News(10 mins):